Neurosense Therapeutics Ltd

Company Profile

Neurosense Therapeutics Ltd had its IPO on 2021-12-09 under the ticker symbol NRSN.

The company operates in the Healthcare sector and Biotechnology industry. Neurosense Therapeutics Ltd has a staff strength of 14 employees.

Stock update

Shares of Neurosense Therapeutics Ltd opened at $0.83 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $0.81 - $0.84, and closed at $0.83.

This is a -1.55% slip from the previous day's closing price.

A total volume of 8,473 shares were traded at the close of the day’s session.

In the last one week, shares of Neurosense Therapeutics Ltd have slipped by -10.42%.

Neurosense Therapeutics Ltd's Key Ratios

Neurosense Therapeutics Ltd has a market cap of $12.53 million, indicating a price to book ratio of 2.3137 and a price to sales ratio of 0.

In the last 12-months Neurosense Therapeutics Ltd’s revenue was $0 with a gross profit of $0 and an EBITDA of $-13798000. The EBITDA ratio measures Neurosense Therapeutics Ltd's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Neurosense Therapeutics Ltd’s operating margin was 0% while its return on assets stood at -89.39% with a return of equity of -368.06%.

In Q2, Neurosense Therapeutics Ltd’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.

Neurosense Therapeutics Ltd’s PE and PEG Ratio

Forward PE

0

Trailing PE

0

PEG

Its diluted EPS in the last 12-months stands at $-1.32 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Neurosense Therapeutics Ltd’s profitability.

Neurosense Therapeutics Ltd stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of -0.9176. Its price to sales ratio in the trailing 12-months stood at 0.

Neurosense Therapeutics Ltd stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets

$7.87 million

Total Liabilities

$3.01 million

Operating Cash Flow

$0

Capital Expenditure

$0

Dividend Payout Ratio

0%

Neurosense Therapeutics Ltd ended 2024 with $7.87 million in total assets and $0 in total liabilities. Its intangible assets were valued at $7.87 million while shareholder equity stood at $-1545000.00.

Neurosense Therapeutics Ltd ended 2024 with $0 in deferred long-term liabilities, $3.01 million in other current liabilities, in common stock, $-29900000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $7.09 million and cash and short-term investments were $7.09 million. The company’s total short-term debt was $0 while long-term debt stood at $0.

Neurosense Therapeutics Ltd’s total current assets stands at $7.56 million while long-term investments were $0 and short-term investments were $0.00. Its net receivables were $434000.00 compared to accounts payable of $1.09 million and inventory worth $0.

In 2024, Neurosense Therapeutics Ltd's operating cash flow was $0 while its capital expenditure stood at $0.

Comparatively, Neurosense Therapeutics Ltd paid $0 in dividends in 2024.

Other key metrics

Current Trading Price

$0.83

52-Week High

$2.91

52-Week Low

$0.79

Analyst Target Price

$7.25

Neurosense Therapeutics Ltd stock is currently trading at $0.83 per share. It touched a 52-week high of $2.91 and a 52-week low of $2.91. Analysts tracking the stock have a 12-month average target price of $7.25.

Its 50-day moving average was $1.11 and 200-day moving average was $1.53 The short ratio stood at 0.23 indicating a short percent outstanding of 0%.

Around 3688.1% of the company’s stock are held by insiders while 94.4% are held by institutions.